Bellizzi Vincenzo, Annunziata Giuseppe, Albanese Alice, D'Alessandro Claudia, Garofalo Carlo, Foletto Mirto, Barrea Luigi, Cupisti Adamasco, Zoccali Carmine, De Nicola Luca
Division of Nephrology "Sant'Anna e San Sebastiano" Hospital, Caserta, Italy.
Facoltà di Scienze Umane, della Formazione e dello Sport, Università Telematica Pegaso, Naples, Italy.
Clin Kidney J. 2024 Nov 22;17(Suppl 2):51-64. doi: 10.1093/ckj/sfae291. eCollection 2024 Dec.
Obesity is recognized as a public health challenge. During the last three decades, the global age-standardized prevalence increased from 8.8% to 18.5% in women and from 4.8% to 14.0% in men, with an absolute current number of 878 million obese subjects. Obesity significantly increases the risk of developing disability and chronic diseases, including chronic kidney disease (CKD). Specifically, obesity acts as a major, modifiable cause of CKD onset and progression toward kidney failure; as such, it is considered by the International Society of Nephrology a major health priority. This review analyses the effectiveness, safety and practicability of non-pharmacological anti-obesity interventions in CKD as the different patient phenotypes that may take advantage of personalized approaches.
肥胖被视为一项公共卫生挑战。在过去三十年中,全球年龄标准化患病率在女性中从8.8%增至18.5%,在男性中从4.8%增至14.0%,目前肥胖者的绝对数量为8.78亿。肥胖显著增加了出现残疾和慢性疾病的风险,包括慢性肾脏病(CKD)。具体而言,肥胖是CKD发病及进展至肾衰竭的一个主要的、可改变的原因;因此,国际肾脏病学会将其视为一项重大的健康优先事项。本综述分析了非药物抗肥胖干预措施在CKD中的有效性、安全性和实用性,以及不同患者表型可能从个性化方法中获益的情况。